Analyst Price Targets — QTNT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 19, 2022 10:19 am | — | Goldman Sachs | $1.50 | $0.70 | Benzinga | Goldman Sachs Maintains Neutral on Quotient, Lowers Price Target to $1.5 |
Latest News for QTNT
Quotient Therapeutics Announces Collaboration with Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck, known as MSD outside the US and Canada, to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient's somatic genomics platform technology.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QTNT.
U.S. House Trading
No House trades found for QTNT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.